The global bladder cancer therapeutics diagnostics market size is calculated at USD 5.68 billion in 2025 and is forecasted to reach around USD 9.53 billion by 2034, accelerating at a CAGR of 5.92% from 2025 to 2034. The North America market size surpassed USD 2.25 billion in 2024 and is expanding at a CAGR of 6.05% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Bladder Cancer Therapeutics Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Bladder Cancer Therapeutics Diagnostics Market, by Type of Diagnostics
8.1.1. Imaging Techniques
8.1.1.1. Market Revenue and Forecast
8.1.2. Urine Cytology
8.1.2.1. Market Revenue and Forecast
8.1.3. Biopsy
8.1.3.1. Market Revenue and Forecast
8.1.4. Urinary Biomarkers
8.1.4.1. Market Revenue and Forecast
9.1.5. Cystoscopy
9.1.5.1. Market Revenue and Forecast
9.1. Bladder Cancer Therapeutics Diagnostics Market, by Treatment Modalities
9.1.1. Chemotherapy
9.1.1.1. Market Revenue and Forecast
9.1.2. Immunotherapy
9.1.2.1. Market Revenue and Forecast
9.1.3. Radiation Therapy
9.1.3.1. Market Revenue and Forecast
9.1.4. Surgery
9.1.4.1. Market Revenue and Forecast
9.1.5. Targeted Therapy
9.1.5.1. Market Revenue and Forecast
10.1. Bladder Cancer Therapeutics Diagnostics Market, by Stage of Cancer
10.1.1. Non-Muscle Invasive
10.1.1.1. Market Revenue and Forecast
10.1.2. Muscle Invasive
10.1.2.1. Market Revenue and Forecast
10.1.3. Metastatic
10.1.3.1. Market Revenue and Forecast
11.1. Bladder Cancer Therapeutics Diagnostics Market, by End User
11.1.1. Hospitals
11.1.1.1. Market Revenue and Forecast
11.1.2. Diagnostic Laboratories
11.1.2.1. Market Revenue and Forecast
11.1.3. Ambulatory Surgical Centers
11.1.3.1. Market Revenue and Forecast
11.1.4. Research and Academic Institutes
11.1.4.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Type of Diagnostics
12.1.2. Market Revenue and Forecast, by Treatment Modalities
12.1.3. Market Revenue and Forecast, by Stage of Cancer
12.1.4. Market Revenue and Forecast, by End User
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Type of Diagnostics
12.1.5.2. Market Revenue and Forecast, by Treatment Modalities
12.1.5.3. Market Revenue and Forecast, by Stage of Cancer
12.1.5.4. Market Revenue and Forecast, by End User
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Type of Diagnostics
12.1.6.2. Market Revenue and Forecast, by Treatment Modalities
12.1.6.3. Market Revenue and Forecast, by Stage of Cancer
12.1.6.4. Market Revenue and Forecast, by End User
12.2. Europe
12.2.1. Market Revenue and Forecast, by Type of Diagnostics
12.2.2. Market Revenue and Forecast, by Treatment Modalities
12.2.3. Market Revenue and Forecast, by Stage of Cancer
12.2.4. Market Revenue and Forecast, by End User
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Type of Diagnostics
12.2.5.2. Market Revenue and Forecast, by Treatment Modalities
12.2.5.3. Market Revenue and Forecast, by Stage of Cancer
12.2.5.4. Market Revenue and Forecast, by End User
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Type of Diagnostics
12.2.6.2. Market Revenue and Forecast, by Treatment Modalities
12.2.6.3. Market Revenue and Forecast, by Stage of Cancer
12.2.6.4. Market Revenue and Forecast, by End User
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Type of Diagnostics
12.2.7.2. Market Revenue and Forecast, by Treatment Modalities
12.2.7.3. Market Revenue and Forecast, by Stage of Cancer
12.2.7.4. Market Revenue and Forecast, by End User
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Type of Diagnostics
12.2.8.2. Market Revenue and Forecast, by Treatment Modalities
12.2.8.3. Market Revenue and Forecast, by Stage of Cancer
12.2.8.4. Market Revenue and Forecast, by End User
12.3. APAC
12.3.1. Market Revenue and Forecast, by Type of Diagnostics
12.3.2. Market Revenue and Forecast, by Treatment Modalities
12.3.3. Market Revenue and Forecast, by Stage of Cancer
12.3.4. Market Revenue and Forecast, by End User
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Type of Diagnostics
12.3.5.2. Market Revenue and Forecast, by Treatment Modalities
12.3.5.3. Market Revenue and Forecast, by Stage of Cancer
12.3.5.4. Market Revenue and Forecast, by End User
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Type of Diagnostics
12.3.6.2. Market Revenue and Forecast, by Treatment Modalities
12.3.6.3. Market Revenue and Forecast, by Stage of Cancer
12.3.6.4. Market Revenue and Forecast, by End User
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Type of Diagnostics
12.3.7.2. Market Revenue and Forecast, by Treatment Modalities
12.3.7.3. Market Revenue and Forecast, by Stage of Cancer
12.3.7.4. Market Revenue and Forecast, by End User
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Type of Diagnostics
12.3.8.2. Market Revenue and Forecast, by Treatment Modalities
12.3.8.3. Market Revenue and Forecast, by Stage of Cancer
12.3.8.4. Market Revenue and Forecast, by End User
12.4. MEA
12.4.1. Market Revenue and Forecast, by Type of Diagnostics
12.4.2. Market Revenue and Forecast, by Treatment Modalities
12.4.3. Market Revenue and Forecast, by Stage of Cancer
12.4.4. Market Revenue and Forecast, by End User
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Type of Diagnostics
12.4.5.2. Market Revenue and Forecast, by Treatment Modalities
12.4.5.3. Market Revenue and Forecast, by Stage of Cancer
12.4.5.4. Market Revenue and Forecast, by End User
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Type of Diagnostics
12.4.6.2. Market Revenue and Forecast, by Treatment Modalities
12.4.6.3. Market Revenue and Forecast, by Stage of Cancer
12.4.6.4. Market Revenue and Forecast, by End User
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Type of Diagnostics
12.4.7.2. Market Revenue and Forecast, by Treatment Modalities
12.4.7.3. Market Revenue and Forecast, by Stage of Cancer
12.4.7.4. Market Revenue and Forecast, by End User
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Type of Diagnostics
12.4.8.2. Market Revenue and Forecast, by Treatment Modalities
12.4.8.3. Market Revenue and Forecast, by Stage of Cancer
12.4.8.4. Market Revenue and Forecast, by End User
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Type of Diagnostics
12.5.2. Market Revenue and Forecast, by Treatment Modalities
12.5.3. Market Revenue and Forecast, by Stage of Cancer
12.5.4. Market Revenue and Forecast, by End User
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Type of Diagnostics
12.5.5.2. Market Revenue and Forecast, by Treatment Modalities
12.5.5.3. Market Revenue and Forecast, by Stage of Cancer
12.5.5.4. Market Revenue and Forecast, by End User
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Type of Diagnostics
12.5.6.2. Market Revenue and Forecast, by Treatment Modalities
12.5.6.3. Market Revenue and Forecast, by Stage of Cancer
12.5.6.4. Market Revenue and Forecast, by End User
13.1. Roche Holding AG
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Genentech Inc
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Advent Health
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Pfizer Inc
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Pfizer Inc
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Novartis AG
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Eli Lilly and Company
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. BristolMyers Squibb Company
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Bayer AG
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Seattle Genetics Inc
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample